期刊
ANTI-CANCER DRUGS
卷 15, 期 10, 页码 991-996出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001813-200411000-00009
关键词
breast cancer; prostate cancer; retinoids; synthetic retinoids; xenografts
资金
- NIAMS NIH HHS [AR 49621] Funding Source: Medline
- NIDDK NIH HHS [DK 59169] Funding Source: Medline
The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen -dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) alpha. Both retinoids also showed similar efficacy against established PC-3 prostate carcinoma xenografts. MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. Tumor xenografts derived from MDA-MB-231 an estrogen-independent breast cancer cell line that expresses low levels of RARalpha, were unresponsive. This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARalpha, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy. (C) 2004 Lippincott Williams Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据